MANILA, Philippines — After missing four games due to an ankle injury, two-time MVP Josh Ybañez made a brief return for University of Santo Tomas in a loss to Ateneo in the UAAP Season 87 men ...

Leqembi’s approval made headlines, and for good reason. More than 6 million Americans live with Alzheimer’s. And 1 in 3 adults ages 65 and older dies with it or another form of dementia ...

Emmerdale fans have "rumbled" the blackmailer behind Manpreet's mysterious texts as they're convinced a character set to exit the soap this year is guilty. Rebecca Sarker first stepped foot in the ...

By using this site, you consent to our User Agreement and agree that your clicks, interactions, and personal information may be collected, recorded, and/or stored by us and social media and other ...

The U.K.’s National Institute for Health and Care Excellence on Thursday again denied to recommend Biogen and Eisai’s Alzheimer’s disease therapy Leqembi, noting that its clinical benefits do not ...

NEW YORK – The UK National Institute for Health and Care Excellence on Thursday issued two updated draft guidances recommending against making Eisai and Biogen's Leqembi (lecanemab) and Eli Lilly's ...

Associations between biomarkers of poor synapse health and higher levels of Alzheimer’s-related proteins in the brain, as well as steeper… The U.S. Food and Drug Administration (FDA) has approved ...

Good morning everyone, it’s Jason Mast, filling in for Ed. Today I’m in Pharmalittle’s New York bureau, sipping a cup poured from a French press gifted to me by my sisters, made from beans ...

Australia’s Therapeutic Goods Administration (TGA) has once again decided against approving Eisai Australia Pty Ltd.’s amyloid beta binder, Leqembi (lecanemab), for treating patients with mild ...

In October 2024, the TGA made the decision not to register lecanemab (LEQEMBI) on the Australian Register of Therapeutic Goods (ARTG) for the treatment of patients with Mild Cognitive Impairment (MCI) ...

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi. The companies on ...

Leqembi (lecanemab-irmb) is a brand-name drug prescribed to treat Alzheimer’s disease in adults with mild cognitive impairment or mild dementia. The drug comes as an intravenous (IV) infusion ...